Hemispherx Biopharma Inc.Find Ratings Reports
HEMISPHERX BIOPHARMA INC's gross profit margin for the third quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its industry. HEMISPHERX BIOPHARMA INC has average liquidity. Currently, the Quick Ratio is 1.07 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 39.62% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY17||Q3 FY16|
|Net Sales ($mil)||0.09||0.02|
|Net Income ($mil)||-1.25||-2.86|
|Balance Sheet||Q3 FY17||Q3 FY16|
|Cash & Equiv. ($mil)||2.3||8.01|
|Total Assets ($mil)||14.73||21.58|
|Total Debt ($mil)||1.47||0.0|
|Profitability||Q3 FY17||Q3 FY16|
|Gross Profit Margin||-2651.11||-13150.0|
|Return on Assets||-50.51||-43.87|
|Return on Equity||-74.08||-56.91|
|Debt||Q3 FY17||Q3 FY16|
|Share Data||Q3 FY17||Q3 FY16|
|Shares outstanding (mil)||31.08||24.11|
|Div / share||0.0||0.0|
|Book value / share||0.32||0.69|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||471942.0||715349.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.18 indicates a significant discount versus the S&P 500 average of 3.18 and a significant discount versus the industry average of 12.11. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, HEMISPHERX BIOPHARMA INC proves to trade at a discount to investment alternatives within the industry.
|HEB NM||Peers 42.11||HEB NM||Peers 28.50|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
HEB's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
HEB's P/CF is negative making the measure meaningless.
|HEB NA||Peers 18.83||HEB NA||Peers 0.36|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|HEB 1.18||Peers 12.11||HEB 38.78||Peers -4.13|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
HEB is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
HEB is expected to have an earnings growth rate that significantly exceeds its peers.
|HEB 29.52||Peers 58.30||HEB 291.26||Peers 551.70|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
HEB is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
HEB significantly trails its peers on the basis of sales growth